By Josh Beckerman
Brainstorm Cell Therapeutics shares rose 5% after hours, to 45 cents, regaining some ground after falling 48% during the regular session Monday.
The shares slipped during the trading day after the U.S. Food and Drug Administration posted documents for a Wednesday advisory committee meeting to discuss NurOwn for Amyotrophic Lateral Sclerosis.
According to an FDA briefing document, the agency’s review team has “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness.”
Write to Josh Beckerman at [email protected]
Read the full article here